Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial
Purpose: A primary analysis of the ongoing NIVAHL trial demonstrated unexpectedly high interim complete response rates to nivolumab-based first-line treatment in early-stage unfavorable Hodgkin lymphoma. However, biomarkers such as metabolic tumor volume (MTV) or total lesion glycolysis (TLG) and th...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
Clinical cancer research
Year: 2021, Jahrgang: 27, Heft: 2, Pages: 402-407 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-20-3303 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-20-3303 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/27/2/402 
|
| Verfasserangaben: | Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Helen Goergen, Horst Müller, Christian Baues, Ulrich Keller, Julia Meissner, Karolin Trautmann-Grill, Andrea Kerkhoff, Michael Fuchs, Stephanie Sasse, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert, Carsten Kobe, and Paul J. Bröckelmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1753571642 | ||
| 003 | DE-627 | ||
| 005 | 20220819161237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210409s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-20-3303 |2 doi | |
| 035 | |a (DE-627)1753571642 | ||
| 035 | |a (DE-599)KXP1753571642 | ||
| 035 | |a (OCoLC)1341404054 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Voltin, Conrad-Amadeus |e VerfasserIn |0 (DE-588)1231103256 |0 (DE-627)1753572312 |4 aut | |
| 245 | 1 | 0 | |a Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma |b a PET-based analysis from the prospective, randomized phase II NIVAHL trial |c Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Helen Goergen, Horst Müller, Christian Baues, Ulrich Keller, Julia Meissner, Karolin Trautmann-Grill, Andrea Kerkhoff, Michael Fuchs, Stephanie Sasse, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert, Carsten Kobe, and Paul J. Bröckelmann |
| 246 | 3 | 0 | |a one |
| 264 | 1 | |c 2021 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online first October 29, 2020 | ||
| 500 | |a Gesehen am 10.08.2021 | ||
| 520 | |a Purpose: A primary analysis of the ongoing NIVAHL trial demonstrated unexpectedly high interim complete response rates to nivolumab-based first-line treatment in early-stage unfavorable Hodgkin lymphoma. However, biomarkers such as metabolic tumor volume (MTV) or total lesion glycolysis (TLG) and their change under treatment (ΔMTV and ΔTLG), measured on PET, might provide additional relevant information for response assessment in this setting. Hence, the current analysis aimed to investigate early response to checkpoint inhibitor therapy beyond conventional criteria. - Patients and Methods: NIVAHL is a prospective, randomized phase II trial that recruited between April 2017 and October 2018. Patients in arms A and B were assessed for early treatment response after two courses of doxorubicin, vinblastine, and dacarbazine with two concomitant nivolumab infusions per cycle (2 × N-AVD) and 4 × nivolumab, respectively. In the current analysis, we included all 59 individuals with PET images available to the central review panel for quantitative analysis before April 30, 2019. - Results: At interim restaging, we determined a mean ΔMTV and ΔTLG of −99.8% each in arm A after 2 × N-AVD, compared with −91.4% and −91.9%, respectively, for treatment group B undergoing 4 × nivolumab. This high decrease in MTV and TLG was observed regardless of the initial lymphoma burden. - Conclusions: Our study showed that nivolumab-based first-line treatment leads to rapid, near-complete reduction of tumor metabolism in early-stage unfavorable Hodgkin lymphoma. Thus, PET-derived biomarkers might allow reduction or even omission of chemotherapy and radiotherapy. Furthermore, MTV and TLG could be also used to optimize immune checkpoint-targeting treatments in other cancers. | ||
| 700 | 1 | |a Mettler, Jasmin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heek, Lutz van |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goergen, Helen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Müller, Horst |e VerfasserIn |4 aut | |
| 700 | 1 | |a Baues, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Keller, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meißner, Julia |e VerfasserIn |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 700 | 1 | |a Trautmann-Grill, Karolin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kerkhoff, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuchs, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sasse, Stephanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tresckow, Bastian von |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dietlein, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borchmann, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Engert, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kobe, Carsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bröckelmann, Paul J. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 27(2021), 2, Seite 402-407 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma a PET-based analysis from the prospective, randomized phase II NIVAHL trial |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:2 |g pages:402-407 |g extent:6 |a Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma a PET-based analysis from the prospective, randomized phase II NIVAHL trial |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-20-3303 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/27/2/402 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210409 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1236765966 |a Meißner, Julia |m 1236765966:Meißner, Julia |d 910000 |d 910100 |e 910000PM1236765966 |e 910100PM1236765966 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 999 | |a KXP-PPN1753571642 |e 3904300636 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"disp":"Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma a PET-based analysis from the prospective, randomized phase II NIVAHL trialClinical cancer research","id":{"issn":["1557-3265"],"zdb":["2036787-9"],"eki":["325489971"]},"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"part":{"volume":"27","issue":"2","text":"27(2021), 2, Seite 402-407","pages":"402-407","year":"2021","extent":"6"},"name":{"displayForm":["American Association for Cancer Research"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1995-","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","publisher":"AACR"}],"corporate":[{"display":"American Association for Cancer Research","role":"isb","roleDisplay":"Herausgebendes Organ"}],"pubHistory":["1.1995 -"],"recId":"325489971"}],"physDesc":[{"extent":"6 S."}],"person":[{"roleDisplay":"VerfasserIn","family":"Voltin","given":"Conrad-Amadeus","role":"aut","display":"Voltin, Conrad-Amadeus"},{"display":"Mettler, Jasmin","role":"aut","given":"Jasmin","roleDisplay":"VerfasserIn","family":"Mettler"},{"family":"Heek","roleDisplay":"VerfasserIn","given":"Lutz van","role":"aut","display":"Heek, Lutz van"},{"given":"Helen","role":"aut","display":"Goergen, Helen","family":"Goergen","roleDisplay":"VerfasserIn"},{"given":"Horst","role":"aut","display":"Müller, Horst","family":"Müller","roleDisplay":"VerfasserIn"},{"given":"Christian","role":"aut","display":"Baues, Christian","family":"Baues","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Keller","given":"Ulrich","display":"Keller, Ulrich","role":"aut"},{"given":"Julia","role":"aut","display":"Meißner, Julia","family":"Meißner","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Trautmann-Grill","display":"Trautmann-Grill, Karolin","role":"aut","given":"Karolin"},{"display":"Kerkhoff, Andrea","role":"aut","given":"Andrea","family":"Kerkhoff","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Fuchs","given":"Michael","role":"aut","display":"Fuchs, Michael"},{"display":"Sasse, Stephanie","role":"aut","given":"Stephanie","family":"Sasse","roleDisplay":"VerfasserIn"},{"display":"Tresckow, Bastian von","role":"aut","given":"Bastian von","roleDisplay":"VerfasserIn","family":"Tresckow"},{"family":"Dietlein","roleDisplay":"VerfasserIn","display":"Dietlein, Markus","role":"aut","given":"Markus"},{"role":"aut","display":"Borchmann, Peter","given":"Peter","family":"Borchmann","roleDisplay":"VerfasserIn"},{"family":"Engert","roleDisplay":"VerfasserIn","role":"aut","display":"Engert, Andreas","given":"Andreas"},{"family":"Kobe","roleDisplay":"VerfasserIn","display":"Kobe, Carsten","role":"aut","given":"Carsten"},{"roleDisplay":"VerfasserIn","family":"Bröckelmann","role":"aut","display":"Bröckelmann, Paul J.","given":"Paul J."}],"name":{"displayForm":["Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Helen Goergen, Horst Müller, Christian Baues, Ulrich Keller, Julia Meissner, Karolin Trautmann-Grill, Andrea Kerkhoff, Michael Fuchs, Stephanie Sasse, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert, Carsten Kobe, and Paul J. Bröckelmann"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2021"}],"language":["eng"],"note":["Published online first October 29, 2020","Gesehen am 10.08.2021"],"recId":"1753571642","id":{"eki":["1753571642"],"doi":["10.1158/1078-0432.CCR-20-3303"]},"title":[{"subtitle":"a PET-based analysis from the prospective, randomized phase II NIVAHL trial","title":"Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma","title_sort":"Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma"}]} | ||
| SRT | |a VOLTINCONREARLYRESPO2021 | ||